ÂÜŔňÂŇÂ×

Dr. Tedder received his Ph.D. in molecular cell biology from the University of Alabama at Birmingham, where he was an American Society for Microbiology President’s Fellow. He was a Damon Runyon-Walter Winchell Research Fellow at Harvard Medical School and Dana-Farber Cancer Institute and joined the faculty in 1985, rising to Associate Professor and principal investigator in the Division of Tumor Immunology at Dana-Farber Cancer Institute. In 1993, Dr. Tedder became the inaugural chairman and professor of Duke University Medical Center’s Department of Immunology and served as director of the Duke Comprehensive Cancer Center Immunobiology Program. He was a Scholar of the Leukemia Society of America and received the LeRoy Collins Distinguished Alumni Award, an NCI/NIH Shannon Award, the Stohlman Scholarship, the Leukemia Society's highest award for research in the field of hematology/oncology, and the Alter Geller Professorship for Research in Immunology at Duke. He founded Cellective Therapeutics in 2003 with the largest Series A financing in the Southeast at that time. The company was acquired by MedImmune/AstraZeneca in 2005. In 2015, he founded Cellective BioTherapy, Inc. and serves as CEO and director. Dr. Tedder has and continues to serve as a consultant and SAB member to more than 20 national and international biopharmaceutical companies and private foundations. He has authored over 400 scientific papers and was recognized as an ISI “100 Most-Cited Authors” in the field of immunology. Dr. Tedder holds 25 patents issued in the U.S.